{"id":7836,"date":"2026-01-26T10:18:00","date_gmt":"2026-01-26T09:18:00","guid":{"rendered":"https:\/\/goba.eu\/copro-projekt-cordycepin-kot-potencialni-farmakoloski-zaviralec-profibroticnih-signalnih-poti-pri-sistemski-sklerozi\/"},"modified":"2026-05-19T12:49:10","modified_gmt":"2026-05-19T11:49:10","slug":"copro-projekt-cordycepin-as-a-potential-pharmacological-inhibitor-of-profibrotic-pathways-in-systemic-sclerosis","status":"publish","type":"post","link":"https:\/\/goba.eu\/en\/copro-projekt-cordycepin-as-a-potential-pharmacological-inhibitor-of-profibrotic-pathways-in-systemic-sclerosis\/","title":{"rendered":"Cordycepin as a potential pharmacological inhibitor of pro-fibrotic pathways in systemic sclerosis"},"content":{"rendered":"<h2><span style=\"font-size: 16px;\">Abstract<\/span><\/h2>\n<p class=\"p1\">Cordycepin has already been studied in vitro and in vivo as potential treatment of various forms of organ fibrosis, such as kidney and renal fibrosis.<\/p>\n<p data-start=\"140\" data-end=\"528\">In the presented study, the authors examined the <strong>effects of cordycepin on fibrotic processes in systemic sclerosis<\/strong> \u2013 a rare autoimmune disease characterized by excessive accumulation of connective tissue in the skin and lungs.<\/p>\n<p data-start=\"140\" data-end=\"528\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-6782 size-full\" src=\"https:\/\/goba.eu\/wp-content\/uploads\/2026\/01\/Cordycepin-in-sistemska-fibroza.png\" alt=\"Cordycepin in sistemska fibroza\" width=\"560\" height=\"400\" srcset=\"https:\/\/goba.eu\/wp-content\/uploads\/2026\/01\/Cordycepin-in-sistemska-fibroza.png 560w, https:\/\/goba.eu\/wp-content\/uploads\/2026\/01\/Cordycepin-in-sistemska-fibroza-300x214.png 300w, https:\/\/goba.eu\/wp-content\/uploads\/2026\/01\/Cordycepin-in-sistemska-fibroza-287x205.png 287w\" sizes=\"auto, (max-width: 560px) 100vw, 560px\" \/><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-6783 size-full\" src=\"https:\/\/goba.eu\/wp-content\/uploads\/2026\/01\/Cordycepin-sistemska-fibroza.png\" alt=\"\" width=\"560\" height=\"400\" srcset=\"https:\/\/goba.eu\/wp-content\/uploads\/2026\/01\/Cordycepin-sistemska-fibroza.png 560w, https:\/\/goba.eu\/wp-content\/uploads\/2026\/01\/Cordycepin-sistemska-fibroza-300x214.png 300w, https:\/\/goba.eu\/wp-content\/uploads\/2026\/01\/Cordycepin-sistemska-fibroza-287x205.png 287w\" sizes=\"auto, (max-width: 560px) 100vw, 560px\" \/><\/p>\n<blockquote class=\"blockquote\"><p>The in vitro results showed that <strong>cordycepin effectively inhibits fibroblast activation<\/strong> and their <strong>transformation into myofibroblasts<\/strong>, while <strong>reducing the production of key extracellular matrix components<\/strong> such as collagen and fibronectin, without exhibiting cytotoxic effects.<\/p><\/blockquote>\n<p data-start=\"791\" data-end=\"1094\"><strong data-start=\"791\" data-end=\"805\">Disclaimer:<\/strong> The results of the presented study are based on in vitro experiments with human dermal and lung fibroblasts. The effects of cordycepin in humans have not yet been clinically confirmed, and further research is needed to validate its efficacy and safety under ex vivo and clinical conditions.<\/p>\n<p data-start=\"1096\" data-end=\"1281\">The findings provide an important foundation for future research on the potential role of cordycepin in modulating profibrotic processes in systemic sclerosis and other forms of fibrosis.<\/p>\n<p data-start=\"1096\" data-end=\"1281\">\n","protected":false},"excerpt":{"rendered":"<p>Abstract<\/p>\n<p>Cordycepin has already been studied in vitro and in vivo as potential treatment of different organ fibrosis, such as kidney and renal fibrosis. In the presented study, the authors investigated the effects of cordycepin on fibrotic processes in systemic sclerosis \u2013 a rare autoimmune disease characterized by excessive accumulation of connective tissue in the skin and lungs.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1072],"tags":[983,985,1313,1096],"class_list":["post-7836","post","type-post","status-publish","format-standard","hentry","category-studies","tag-cordycepin","tag-cordyceps","tag-fibrosis","tag-systemic-sclerosis"],"acf":[],"_links":{"self":[{"href":"https:\/\/goba.eu\/en\/wp-json\/wp\/v2\/posts\/7836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/goba.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/goba.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/goba.eu\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/goba.eu\/en\/wp-json\/wp\/v2\/comments?post=7836"}],"version-history":[{"count":8,"href":"https:\/\/goba.eu\/en\/wp-json\/wp\/v2\/posts\/7836\/revisions"}],"predecessor-version":[{"id":12013,"href":"https:\/\/goba.eu\/en\/wp-json\/wp\/v2\/posts\/7836\/revisions\/12013"}],"wp:attachment":[{"href":"https:\/\/goba.eu\/en\/wp-json\/wp\/v2\/media?parent=7836"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/goba.eu\/en\/wp-json\/wp\/v2\/categories?post=7836"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/goba.eu\/en\/wp-json\/wp\/v2\/tags?post=7836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}